Cohort characteristics overall and by 1-month PCP contact status
| Characteristic | PCP Contact <1 month N (%) 394 (46.5%) | No PCP contact <1 month N (%) 453 (53.5%) | All participants N (%) N=847 | p Value |
|---|---|---|---|---|
| Gender (N, %) | ||||
| Female | 109 (27.7) | 80 (17.7) | 189 (22.3) | |
| Male | 285 (72.3) | 373 (82.3) | 658 (77.7) | |
| 847 (100.0) | <0.001* | |||
| Age (years±SD) | 37.4±12.9 | 31.5±9.6 | 34.2±11.6 | <0.001† |
| Age (years) (N, %) | ||||
| <25 | 64 (16.2) | 142 (31.4) | 206 (24.3) | |
| 25–29 | 67 (17.0) | 91 (20.1) | 158 (18.7) | |
| 30–39 | 128 (32.5) | 137 (30.2) | 265 (31.3) | |
| ≥40 | 135 (34.3) | 83 (18.3) | 218 (25.7) | |
| 847 (100.0) | <0.001* | |||
| Indigenous status (N, %) | ||||
| Indigenous | 63 (16.0) | 96 (21.2) | 159 (18.8) | |
| Non-indigenous | 331 (84.0) | 357 (78.8) | 688 (81.2) | |
| 847 (100.0) | 0.053* | |||
| Lifetime chronic conditions (N, %) | ||||
| Yes | 303 (76.9) | 278 (61.4) | 581 (68.6) | |
| No | 91 (23.1) | 175 (38.6) | 266 (31.4) | |
| 847 (100.0) | <0.001* | |||
| CNS medications (N, %) | ||||
| Yes | 157 (42.4) | 87 (20.3) | 244 (30.5) | |
| No | 213 (57.6) | 342 (79.7) | 555 (69.5) | |
| 799 (94.3)‡ | <0.001* | |||
| Non-CNS medications (N, %) | ||||
| Yes | 172 (46.5) | 72 (16.8) | 244 (30.5) | |
| No | 198 (53.5) | 357 (83.2) | 555 (69.5) | |
| 799 (94.3)‡ | <0.001* | |||
| Social visits in prison (N, %) | ||||
| Yes | 204 (51.8) | 239 (52.8) | 443 (52.3) | |
| No | 190 (48.2) | 214 (47.2) | 404 (47.7) | |
| 847 (100.0) | 0.775* | |||
| Lifetime Hep C exposure status (N, %) | ||||
| Positive | 114 (28.9) | 120 (26.5) | 234 (27.6) | |
| Negative | 280 (71.1) | 333 (73.5) | 613 (72.4) | |
| 847 (100.0) | 0.428* | |||
| PAM score (N, %) | ||||
| ≤41 | 49 (12.4) | 53 (11.7) | 102 (12.0) | |
| >41 | 345 (87.6) | 400 (88.3) | 745 (88.0) | |
| 847 (100.0) | 0.742* | |||
| K10 distress (N, %) | ||||
| Low/moderate | 271 (69.0) | 355 (78.5) | 626 (74.1) | |
| High/very high | 122 (31.0) | 97 (21.5) | 219 (25.9) | |
| 845 (99.8)‡ | 0.002* | |||
| HASI score <85 (N, %) | ||||
| Yes | 89 (22.8) | 91 (20.4) | 180 (21.5) | |
| No | 301 (77.2) | 356 (79.6) | 657 (78.5) | |
| 837 (98.8)‡ | 0.387* | |||
| Transitional programs participation (N, %) | ||||
| Yes | 86 (21.8) | 76 (16.8) | 162 (19.1) | |
| No | 308 (78.2) | 377 (83.2) | 685 (80.9) | |
| 847 (100.0) | 0.062* | |||
| Postrelease supervision orders (N, %) | ||||
| Yes | 246 (62.4) | 289 (63.9) | 535 (63.2) | |
| No | 148 (37.6) | 163 (36.1) | 311 (36.8) | |
| 846 (99.9)‡ | 0.651* | |||
| Juvenile incarceration history (N, %) | ||||
| Yes | 74 (19.0) | 99 (22.1) | 173 (20.6) | |
| No | 316 (81.0) | 350 (77.9) | 666 (79.4) | |
| 839 (99.1)‡ | 0.272* | |||
| Adult prison sentence (N, %) | ||||
| First | 164 (41.7) | 176 (38.9) | 340 (40.2) | |
| Repeat | 229 (58.3) | 277 (61.1) | 506 (59.8) | |
| 846 (99.9)‡ | 0.394* | |||
*Pearson χ2 test.
†Independent t test.
‡Total sums to less than 100% due to missing outcome data.
CNS, central nervous system; HASI, Hayes Ability Screening Index; Hep C, hepatitis C; K10, Kessler Psychological Distress Scale; PAM, Patient Activation Measure.